STOCK TITAN
  1. Home
  2. News
  3. VCNX

Vaccinex Inc - VCNX STOCK NEWS

Welcome to our dedicated news page for Vaccinex (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaccinex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaccinex's position in the market.

News
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Vaccinex, Inc. announced financial results and clinical updates, including progress on pepinemab for Alzheimer's Disease and Head and Neck Cancer. Topline data for the Phase 1/2a SIGNAL-AD study is expected in Q3 2024, with $17.9 million raised in new financing. Pepinemab targets SEMA4D, a key player in neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
earnings
-
News
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Vaccinex, Inc. announced a registered direct offering and concurrent private placement of 193,000 shares of common stock with warrants, priced at $7.77 per share. The company aims to raise funds for its innovative approach to treating Alzheimer's disease and cancer through SEMA4D inhibition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
offering
-
News
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Rhea-AI Summary
Vaccinex, Inc. announces eight new antibody discovery agreements utilizing its ActivMAb platform to select antibodies against challenging transmembrane protein targets. The company has partnered with major pharma and biotech companies and antibody service providers to accelerate drug discovery. The ActivMAb system allows for the development of antibodies targeting complex protein targets crucial for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
none
News
Vaccinex, Inc. Announces Reverse Stock Split
Rhea-AI Summary
Vaccinex, Inc. (VCNX) announces a 1-for-14 reverse stock split to regain Nasdaq compliance. Stockholders approved the split to meet the $1.00 minimum bid price requirement. The split aims to ensure the closing bid price remains above $1.00 for 10 consecutive business days by March 4, 2024. The reverse stock split will not affect total authorized shares or ownership percentages but will combine every fourteen shares into one share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
stock split
-
News
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
Rhea-AI Summary
Vaccinex, Inc. announces a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors. The offering includes the sale of 3,838,544 shares of common stock and 1,265,078 common stock equivalents, together with common warrants to purchase up to 5,103,622 shares of common stock. The offering is expected to close on or before February 8, 2024, and the gross proceeds are expected to be $3.7 million. The financing, along with other commitments, is anticipated to fully fund the ongoing SIGNAL-AD trial through the release of topline data in the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
none
-
News
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
Rhea-AI Summary
Vaccinex, Inc. (Nasdaq: VCNX) has reassured Nasdaq of actions it plans to take to meet the minimum bid price requirement. The company has been granted an exception until March 4, 2024, to address this issue. Vaccinex is also on schedule to complete the treatment for a randomized phase 2 study in Alzheimer’s disease by June 2024, with a focus on potential near-term catalysts and key endpoints including brain metabolic activity and treatment effects on cognition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.74%
Tags
none
News
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Vaccinex, Inc. (Nasdaq: VCNX) Achieves Full Accrual in Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease, Raises Over $10 Million in New Financing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
earnings
-
News
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Rhea-AI Summary
Vaccinex, Inc. will be presenting novel findings for its lead product, pepinemab, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The studies demonstrate that pepinemab induces the formation of lymphoid structures in tumors, which promote efficient immune responses and improved outcomes to immune checkpoint inhibitors. In the Phase 2 KEYNOTE-B84 study, pepinemab in combination with Merck's anti-PD-1 therapy showed a doubling of objective responses and progression-free survival in patients with hard-to-treat tumors. Another study with collaborators at Emory University showed that pepinemab in combination with nivolumab and/or ipilimumab induced tertiary lymphoid structures in tumors, resulting in ongoing response in 8 out of 8 patients for more than 2 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
clinical trial
-
News
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
Rhea-AI Summary
Vaccinex reports positive findings for its lead product, pepinemab, in treating brain inflammation. The drug significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, indicating its potential to reverse harmful astrocyte activation. A randomized, placebo-controlled trial is currently underway to test the drug's effectiveness in Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
none
News
Vaccinex Announces Pricing of $9.6 Million Public Offering
Rhea-AI Summary
Vaccinex, Inc. announces securities purchase agreements for the sale of 9.6M shares of common stock and warrants, expected to raise $9.6M in gross proceeds. The funds will be used for the development of its lead drug candidate and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.17%
Tags
offering
Stock VCNX logo
Vaccinex Inc

Nasdaq:VCNX

VCNX Rankings

N/A Ranked by Market Cap
#5454 Ranked by Stock Gains
N/A Ranked by Dividends

VCNX Stock Data

9.66M
591.10k
6.76%
41.7%
0.44%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Rochester

About VCNX

located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop